Related Experiment Video
Updated: May 21, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Current and future systemic treatments for renal cell carcinoma
Rosalie Fisher1, Martin Gore, James Larkin
1Royal Marsden Hospital, London, UK.
Seminars in Cancer Biology
|June 19, 2012
Summary
Systemic treatments for advanced renal cell carcinoma have evolved significantly, improving survival but remaining palliative. Emerging therapies and personalized approaches targeting tumor biology offer future treatment potential.
Area of Science:
- Oncology
- Medical Research
Background:
- Systemic treatment for renal cell carcinoma (RCC) has undergone significant advancements since 2007.
- Six novel agents targeting tumor angiogenesis, proliferation, and survival pathways have been approved.
- Current treatments improve survival in metastatic RCC but are palliative.
Purpose of the Study:
- To review current and emerging systemic treatments for advanced, clear cell metastatic renal cell carcinoma.
- To discuss the integration of systemic therapies with surgical interventions.
- To highlight the shift towards individualized therapy based on tumor biology.
Main Methods:
- Review of current literature on systemic treatments for renal cell carcinoma.
- Analysis of clinical development of newer agents and research methodologies.
- Focus on advanced, clear cell metastatic renal cell carcinoma.
Main Results:
- Significant improvements in survival times for metastatic RCC patients.
- Identification of six new systemic agents impacting key molecular pathways.
- Emerging agents in clinical development with theoretical advantages.
Conclusions:
- Systemic therapy has dramatically improved outcomes in metastatic RCC.
- Future directions include novel agents and personalized treatment strategies.
- Integration of systemic and surgical therapy is crucial for advanced RCC management.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...